E2F8

Across TCGA pan-cancer cohorts, E2F8 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated E2F8 data layer compared with 27 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher E2F8 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated E2F8 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, UCEC, and LAML are the cancer types where E2F8 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.090	0.812	<.001	24	view →
UCEC	DFS	Median	All	0.902	0.615	.012	14	view →
LAML	DFS	Median	All	0.112	0.582	.010	12	view →
SKCM	DFS	Median	III,IV	0.063	0.648	.003	7	view →
LUSC	DFS	Median	III,IV	0.207	0.639	.021	6	view →
BLCA	OS	Median	IV	0.141	0.573	.034	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

E2F8–LUAD (OS)

Open the LUAD breakdown →